Protective role of interlekin-1 alpha gene polymorphism in Chinese Han population with sporadic Parkinson's disease

Neuroscience Letters

Volumn 445, Issue 1, 2008, Pages 23-25

  Zhou, Yong tao ^a   Yang, Jin fang ^a   Zhang, Yan li ^a   Wang, Xing yu ^b   Chan, Piu ^a  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^b Beijing Hypertension League Institute   (China)

Author keywords

Interleukin 1 alpha gene; Parkinson's disease; Polymorphism

Indexed keywords

CYTOKINE; INTERLEUKIN 1 ALPHA PROTEIN; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; SURVIVAL;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CHI-SQUARE DISTRIBUTION; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTERLEUKIN-1ALPHA; MALE; MIDDLE AGED; PARKINSON DISEASE; POLYMORPHISM, GENETIC; RISK;

EID: 53149115570     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2008.08.054     Document Type: Article

References (24)

1. 's disease patients. Neurosci. Lett. 202 (1995) 17-20 (PubMed: 8787820)
2. Chen H., Jacobs E., Schwarzschild M.A., McCullough M.L., Calle E.E., Thun M.J., and Ascherio A. Nonsteroidal anti-inflammatory drug use and the risk of Parkinson's disease. Ann. Neurol. l59 (2005) 988-989 (PubMed: 16241721)
3. Chen H., Zhang S.M., Hernan M.A., Schwarzschild M.A., Willett W.C., Colditz G.A., Speizer F.E., and Ascherio A. Nonsteroidal anti-inflammatory drug and the risk of Parkinson disease. Arch. Neurol. 60 (2003) 1059-1064 (PubMed: 12925360)
4. Dodel R.C., Lohmuller F., Du Y., Eastwood B., Gocke P., Oertel W.H., and Gasser T. A polymorphism in the intronic region of the IL-1alpha gene and the risk for Parkinson's disease. Neurology 10 56(7) (2001) 982-983 (PubMed: 1294947)
5. Hald A., and Lotharius J. Oxidative stress and inflammation in Parkinson's disease: is there a causal link?. Exp. Neurol. 193 (2005) 279-290 (PubMed: 15869932)
6. Hébert G., Mingam R., Arsaut J., Dantzer R., and Demotes-Mainard J. Cellular distribution of interleukin-1alpha-immunoreactivity after MPTP intoxication in mice. Brain Res. Mol. Brain Res. 138 (2005) 156-163 (PubMed: 15922486)
7. Hirsch E.C., Breidert T., Rousselet E., Hunot S., Hartmann A., and Michel P.P. The role of glial reaction and inflammation in Parkinson's disease. Ann. N Y Acad. Sci. 991 (2003) 214-228 (PubMed: 12846989)
8. Hunot S., Dugas N., Faucheux B., Hartmann A., Tardieu M., Debre P., Agid Y., Dugas B., and Hirsch E.C. FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glialcells. J. Neurosci. 19 (1999) 3440-3447 (PubMed: 10212304)
9. Litvan I., Bhatia K.P., Burn D.J., Goetz C.G., Lang A.E., McKeith I., Quinn N., Sethi K.D., Shults C., and Wenning G.K. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov. Disord. 18 (2003) 467-486 (PubMed: 12722160)
10. 's disease in Finnish patients. J. Med. Genet. 39 (2002) 400-402 (PubMed: 12070246)
11. McGeer P.L., Yasojima K., and McGeer E.G. Association of interleukin-1beta polymorphisms with idiopathic Parkinson's disease. Neurosci. Lett. 326 (2002) 67-69 (PubMed: 12052540)
12. Mogi M., Harada M., Kondo T., Riederer P., Inagaki H., Minami M., and Nagatsu T. Interleukin-1beta, interleukin-6, epidermalgrowth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci. Lett. 180 (1994) 147-150 (PubMed: 7700568)
13. Mogi M., Harada M., Narabayashi H., Inagaki H., Minami M., and Nagatsu T. Interleukin (IL)-1beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile Parkinsonism and Parkinson's disease. Neurosci. Lett. 211 (1996) 13-16 (PubMed: 8809836)
14. Mogi M., Harada M., Riederer P., Narabayashi H., Fujita K., and Nagatsu T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci. Lett. 165 (1994) 208-210 (PubMed: 8015728)
15. Moller J.C., Depboylu C., Kolsch H., Lohmuller F., Bandmann O., Gocke P., Du Y., Paus S., Wullner U., Gasser T., Oertel W.H., Klockgether T., and Dodel R.C. Lack of association between the interleukin-1 alpha (-889) polymorphism and early-onset Parkinson's disease. Neurosci. Lett. 359 (2004) 195-197 (PubMed: 15050696)
16. 's disease. Acta Neurol. Scand. 98 (1998) 142-144 (PubMed: 9724016)
17. Nagatsu T., and Sawada M. Inflammatory process in Parkinson's disease: role for cytokines. Curr. Pharm. Des. 11 (2005) 999-1016 (PubMed: 15777250)
18. Nagatsu T., and Sawada M. Cellular and molecular mechanisms of Parkinson's disease: neurotoxins, causative genes, and inflammatory cytokines. Cell Mol. Neurobiol. 26 (2006) 781-802. (PubMed: 16823625)
19. Schulte T., Schöls L., Müller T., Woitalla D., Berger K., and Krüger R. Polymorphisms in the interleukin-1 alpha and beta genes and the risk for Parkinson's disease. Neurosci. Lett. 326 June (1) (2002) 70-72 (PubMed: 12052541)
20. Schultzberg M., Lindberg C., Aronsson A.F., Hjorth E., Spulber S.D., and Oprica M. Inflammation in the nervous system-physiological and pathophysiological aspects. Physiol. Behav. 92 (2007) 121-128 (PubMed: 17597167)
21. Simi A., Tsakiri N., Wang P., and Rothwell N.J. Interleukin-1 and inflammatory neurodegeneration. Biochem. Soc. Trans. 35 (2007) 1122-1126 (PMID: 17956293)
22. Wersinger C., and Sidhu A. Inflammation and Parkinson's disease. Curr. Drug Targets Inflamm. Allergy 1 (2002) 221-242 (PubMed: 14561187)
23. Whitton P.S. Inflammation as a causative factor in the aetiology of Parkinson's disease. Br. J. Pharmacol. 150 (2007) 963-976 (PubMed: 17339843)
24. Zhou Y.T., Zhang Z.X., Zhang J.W., He X.M., and Xu T. Association between interleukin-1 alpha-889 C/T polymorphism and Alzheimer's disease in Chinese Han population. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 28 (2006) 186-190 (PubMed: 16733901)